Related Experiment Videos
Rational approaches to resistance: nucleoside analogues
1Walter Reed Army Institute of Research, Rockville, Maryland, USA.
AIDS (London, England)
|November 1, 1996
Summary
Emergence of HIV-1 drug resistance to nucleoside reverse transcriptase inhibitors is influenced by various factors. Combination therapy, including protease inhibitors, can delay resistance and improve patient outcomes.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- HIV-1 drug resistance is a significant clinical challenge.
- Nucleoside reverse transcriptase inhibitors (NRTIs) are a cornerstone of HIV treatment.
- Understanding resistance patterns is crucial for effective patient management.
Purpose of the Study:
- To review knowledge of drug-resistance patterns to nucleoside HIV reverse transcriptase inhibitors.
- To explore how this knowledge can be leveraged for improved patient management.
Main Methods:
- Review of existing literature on HIV-1 drug resistance to NRTIs.
- Analysis of factors influencing the speed and patterns of resistance emergence.
- Evaluation of strategies for suppressing or delaying drug resistance.
Main Results:
- Resistance to zidovudine develops over months to years, involving specific mutations.
- Other NRTIs like didanosine, zalcitabine, and stavudine show slower resistance development.
- Lamivudine resistance emerges rapidly, with significant susceptibility reduction.
- Cross-resistance exists among certain nucleoside analogs.
- Combination therapy with protease inhibitors and NRTIs delays resistance and multidrug resistance.
Conclusions:
- Widespread use of NRTIs has led to the emergence of resistant HIV strains.
- Transmission of drug-resistant HIV is a growing concern.
- Combination therapy with protease inhibitors and NRTIs can suppress viral replication, prolong treatment efficacy, and benefit patients.